Literature DB >> 23566897

Developmental neurotoxicity of ketamine in pediatric clinical use.

Chaoxuan Dong1, K J S Anand.   

Abstract

Ketamine is widely used as an anesthetic, analgesic, and sedative in pediatric clinical practice and it is also listed as an illicit drug by most countries. Recent in vivo and in vitro animal studies have confirmed that ketamine can induce neuronal cell death in the immature brain, resulting from widespread neuronal apoptosis. These effects can disturb normal development further altering the structure and functions of the brain. Our recent studies further indicate that ketamine can alter neurogenesis from neural stem progenitor cells in the developing brain. Taken together, these findings identify a novel complication associated with ketamine use in premature infants, term newborns, and pregnant women. Recent data on the developmental neurotoxicity of ketamine are reviewed with proposed future directions for evaluating the safety of ketamine in these patient populations.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23566897     DOI: 10.1016/j.toxlet.2013.03.030

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  26 in total

1.  Anesthetic Ketamine-Induced DNA Damage in Different Cell Types In Vivo.

Authors:  Daniela Dimer Leffa; Bruno Nunes Bristot; Adriani Paganini Damiani; Gabriela Daminelli Borges; Francine Daumann; Gabriela Maria Zambon; Gabriela Elibio Fagundes; Vanessa Moraes de Andrade
Journal:  Mol Neurobiol       Date:  2015-10-17       Impact factor: 5.590

2.  Sedation and analgesia practices at Italian neonatal intensive care units: results from the EUROPAIN study.

Authors:  Paola Lago; Anna Chiara Frigo; Eugenio Baraldi; Roberta Pozzato; Emilie Courtois; Jérôme Rambaud; Kanwaljeet J S Anand; Ricardo Carbajal
Journal:  Ital J Pediatr       Date:  2017-03-07       Impact factor: 2.638

3.  Safety and Utility of Continuous Ketamine Infusion for Sedation in Mechanically Ventilated Pediatric Patients.

Authors:  Amy L Heiberger; Surachat Ngorsuraches; Gokhan Olgun; Lisa Luze; Caitlin Leimbach; Holly Madison; Saquib A Lakhani
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

4.  Inhibition of GSK-3beta Signaling Pathway Rescues Ketamine-Induced Neurotoxicity in Neural Stem Cell-Derived Neurons.

Authors:  Jingjing Zhang; Changlei Cui; Yanhui Li; Haiyang Xu
Journal:  Neuromolecular Med       Date:  2017-12-07       Impact factor: 3.843

5.  Neurotransmitter signaling pathways required for normal development in Xenopus laevis embryos: a pharmacological survey screen.

Authors:  Kelly G Sullivan; Michael Levin
Journal:  J Anat       Date:  2016-04-07       Impact factor: 2.610

6.  Ketamine exposure in early development impairs specification of the primary germ cell layers.

Authors:  Oluwaseun Akeju; Brandi N Davis-Dusenbery; Seth H Cassel; Justin K Ichida; Kevin Eggan
Journal:  Neurotoxicol Teratol       Date:  2014-04-16       Impact factor: 3.763

7.  Developmental toxicity assay using high content screening of zebrafish embryos.

Authors:  Susan Lantz-McPeak; Xiaoqing Guo; Elvis Cuevas; Melanie Dumas; Glenn D Newport; Syed F Ali; Merle G Paule; Jyotshna Kanungo
Journal:  J Appl Toxicol       Date:  2014-05-28       Impact factor: 3.446

8.  Behavioral alterations of zebrafish larvae after early embryonic exposure to ketamine.

Authors:  Luís M Félix; Luís M Antunes; Ana M Coimbra; Ana M Valentim
Journal:  Psychopharmacology (Berl)       Date:  2016-12-08       Impact factor: 4.530

9.  Upregulation of miR-137 protects anesthesia-induced hippocampal neurodegeneration.

Authors:  Changshun Huang; Xingcai Zhang; Jungang Zheng; Chunru Chen; Yijun Chen; Juan Yi
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

10.  Ketamine exposure during embryogenesis inhibits cellular proliferation in rat fetal cortical neurogenic regions.

Authors:  C Dong; C R Rovnaghi; K J S Anand
Journal:  Acta Anaesthesiol Scand       Date:  2016-01-29       Impact factor: 2.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.